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OR3
THE DIRECT AND INDIRECT COSTS ASSOCIATED WITH HYPOGONADISM
AMONG PRIVATELY-INSURED EMPLOYEES IN THE UNITED STATES
Kaltenboeck A1, Foster S2, Thomas N2, Ivanova J1, Diener M1, Bergman R1, Birnbaum H3,
Swindle R2
1Analysis Group, Inc., New York, NY, USA, 2Eli Lilly and Company, Indianapolis, IN, USA,
3Analysis Group, Inc., Boston, MA, USA
OBJECTIVES: Compare direct and indirect (workloss) costs between privately-in-
suredU.S. employeeswith hypogonadism (HG) and demographicallymatched con-
trols without HG. METHODS: Male employees, ages 35-64, with 2 HG diagnoses
(ICD-9-CM: 257.2x) or 1 HG diagnosis and 1 claim for testosterone therapy be-
tween 1/1/2005-3/31/2009were identified from a privately-insured claims database
(N12,000,000). The index date was defined as the most recent HG diagnosis with
continuous eligibility 1 year before (baseline period) and 1 year after (study pe-
riod). EmployeeswithHGwerematched 1:1 on age, region, employment status, and
index year to controls without HG. Descriptive analyses compared demographic
characteristics, comorbidities, resource utilization, direct costs (reimbursements
to providers for medical services and prescription drugs) and indirect costs (dis-
ability andmedically-related absenteeism) inflated to $2009. Multivariate analyses
adjusting for baseline patient differences were used to estimate risk-adjusted
costs. RESULTS: 4,269 HG employees, mean age 51, with matched controls met
inclusion criteria. Compared with controls, HG employees had higher baseline co-
morbidity rates: hyperlipidemia (50.2% vs. 25.3%), hypertension (37.7% vs. 21.1%),
back/neck pain (32.0% vs. 15.7%), and HIV/AIDS (7.1% vs. 0.3%) (all p0.0001). HG
employees had higher study period rates of inpatient stays (10.8% vs. 5.2%), Emer-
gency Department visits (27.5% vs. 16.3%), outpatient visits (100.0% vs. 76.7%), pre-
scriptionmedication use (95.7% vs. 68.3%), and highermeanworkloss days (19.3 vs.
8.8) (all p0.0001). HG employees compared with controls had higher mean study
period direct ($10,914 vs. $3,823) and indirect costs ($3,204 vs. $1,450); HG-related
direct costs were $832. HG employees’ costs remained higher after adjusting for
baseline differences (direct: $9,291 vs. $5,248; indirect: $2,729 vs. $1,840) (all
p0.0001). CONCLUSIONS: Employees with HG had higher comorbidity rates and
costs comparedwith demographicallymatched controls. Given the lowHG-related
costs, themain driver of overall costs among HG patientsmay be their comorbidity
burden.
OR4
ASSOCIATIONS BETWEEN JOBLESSNESS AND ALL-CAUSE HEALTH SERVICES
UTILIZATION IN DIABETIC WORKING AGE ADULTS IN THE UNITED STATES
Davis-Ajami ML1, Nahata M1, Seiber E1, Reardon G2, Balkrishnan R3
1Ohio State University, Columbus, OH, USA, 2Informagenics, LLC, Worthington, OH, USA,
3University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To assess associations between joblessness and all-cause emergency
department (ED), hospitalization, outpatient and office-based health services uti-
lization in US diabetic working-age adults. METHODS: This retrospective longitu-
dinal panel design used nationally-representative 2001 – 2007 pooled public do-
main complete panel data from the Medical Expenditure Panel Survey (MEPS).
Eligible MEPS respondents aged 24–59 years with an ICD-9-CM diabetes diagnostic
code “250”, were included. Those with pregnancy diagnostic codes, seasonal job
status, or prescribed insulin were excluded. Subjects reporting an employment
status as “not employed with no job to return to” were classified as jobless. Using
MEPSweights to account for the complex survey design, logistic regressionmodels
estimated associations between joblessness and the likelihood of utilization. Neg-
ative binomial regression models assessed number of utilizations. The Taylor lin-
earization method estimated variance. RESULTS: 2,678 subjects (means: age 48.7
years [SD 0.28], BMI 31.5 [SD 0.30], Charlson Comorbidity Index 0.369 [SD 0.12]) met
eligibility criteria. Compared to those employed, joblessness significantly in-
creased the odds for all-cause ED utilization 64% (OR 1.64, p 0.007) outpatient
visits 46% (OR 1.46, p 0.011) and office-based visit 45%, (OR 1.45, p 0.009). Job-
lessness was associated with higher logs of expected counts for ED visits ( 0.43,
p 0.005) outpatient visits ( 0.49, p 0.002), and office-based visits 41% ( 0.41,
p0.000). The following covariates showed significant (p0.05) associations across
ED, hospitalization, outpatient and office-based utilization sectors: family size, age,
the Charlson Comorbidity Index, and the presence of one or more diabetes related
complication. Hispanic ethnicitywas associatedwith fewer ED visits (0.51, p
0.001), and fewer hospitalizations ( 0.41, p  0.026) than other ethnicities.
Though non-significant, compared to uninsured individuals, private and public
health insurance coverage also showed increased odds and number of utilizations.
CONCLUSIONS: Joblessness was significantly associated with increased all-cause
health services utilization.
PODIUM SESSION I:
CASE STUDIES IN ADDRESSING SELECTION BIAS
SB1
COMPARISON OF DIFFERENCE-IN-DIFFERENCE, PROPENSITY SCORE MATCHING
AND INSTRUMENTAL VARIABLES IN ESTIMATING COST DIFFERENCES
BETWEEN TWO COHORTS
Cao Z, Song X
Thomson Reuters, Cambridge, MA, USA
OBJECTIVES: Endogeneity is a common problem in retrospective claims data stud-
ies because patients in claims data were not assigned to treatment by randomiza-
tion. Propensity score matching (PSM), instrumental variables (IV), and difference-
in-difference (DID) have been used to control for selection bias in evaluating the
impact of treatment on outcome measures. This study compares the estimated
incremental costs between typical and atypical antipsychotic medication users in
patients with schizophrenia using these three methods. METHODS: Patients ages
18-64 years old with at least one prescription of typical or atypical antipsychotic
medication and at least one diagnosis claim of schizophrenia (ICD-9-CM diagnosis
295.xx) within 90 days of the antipsychotic medication were identified in Market-
Scan®Multi-State Medicaid Database 2002–2009. The index date was the first pre-
scription date of antipsychotic medication. All patients had 12-month continu-
ous enrollment prior to and post the index date. Outcomes were total all-cause
expenditures and psychiatric-related expenditures during the 12-month follow up.
The incremental costs associated with the use of typical antipsychotic medication
versus atypical medication was estimated using six regression models–three esti-
mation methods (GLM, IV, and DID) on two samples (matched and non-matched
sample). IV was prescribing physicians’ characteristics. RESULTS: A total of 447
atypical and 4544 typical antipsychotic usersmet all study criteria, with amean age
of 38.9. Five out of the six models (with the exception of the DID model on the
unmatched sample) did not find a significant relationship between types of anti-
psychotic medications and total costs, and five out of the six models (with the
exception of the IV model on the full unmatched sample) found atypical medica-
tion users had significantly higher psychiatric-related costs than typical medica-
tion users. CONCLUSIONS: The PS-based approach combined with the DID or IV
methods may be better than each approach alone.
SB2
ZEROS AND NON-REPORTED HEALTH CARE AND WORKPLACE PRODUCTIVITY
DATA: AN APPLICATION OF TWO-STAGE ESTIMATION TECHNIQUES
MEASURING INPATIENT COSTS AND ABSENTEEISM ASSOCIATED WITH LOW
BACK AND NECK PAIN
Simons WR1, Chow W2, Biondi D2, Benson C2, Kim M2
1Global Health Economics & Outcomes Research Inc., Summit, NJ, USA, 2Ortho-McNeil Janssen
Scientific Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: Abundance of zero values is commonly observed in cost data result-
ing in skewed distribution. This analysis measured the inpatient cost and work-
place absenteeism associated with low back and neck pain and demonstrated the
consequences of ignoring zeros in inpatient cost and unreported absenteeism.
METHODS: We used employer-based claims from the Thomson Marketscan© Re-
search Database (2007), a database representing approximately 100 payers of insured
employees containing health and productivity management (HPM) and health care
utilization data. Adult insured employees with continuous eligibility in 2007 were
included. The ICD-9 codes identifiedmedical conditions including low back and neck
pain without (nociceptive pain, NOCI) or with a neuropathic component (mixed pain,
MIXED).Ordinary least squares (OLS) and two-stageTobit analyses evaluated themar-
ginal inpatient costs while OLS and Heckman’s Selection Bias (HSB) were applied to
absenteeism data. Estimated inpatient costs and absenteeism using OLS versus two-
stage techniques were compared. RESULTS: A total of 2,046,332 employees
(male59.2%; mean age 40.211.6 years) were analyzed. Hypertension (9.8%), NOCI
(9.5%), diabetes (3.7%), MIXED (3.0%) and depression (1.1%) were the most prevalent
medical conditions among these employees. 1,976,952 (96.6%) employees had no in-
patientepisodes, thus,withno inpatient costs.Mean inpatient cost for theentire study
population was $537.45 (median$0) versus $15,851.93 (median $8,302.20) among
thosewith inpatient episodes. The incremental inpatient costs associatedwithMIXED
andNOCIwere $1,333.0226.67 and $328.3615.63 usingOLS versus $2,478.97 [95%CI:
2,148.50 – 2,811.16] and $1,242.41 [95%CI: 1,020.10 – 1,469.18] using the two-stage Tobit.
Unreported absenteeism occurred in 80% of the employees. Annual absenteeism as-
sociated with MIXED and NOCI using OLS were 5.250.21 and 4.060.35 compared to
45.921.06 and 16.332.01 hours using the HSB technique. CONCLUSIONS: Ignoring
zeros in cost data and unreported absenteeismmay result in substantial underes-
timation of inpatient cost and workplace absenteeism associated with low back
and neck pain.
SB3
INNOVATIVE DESIGN FOR A COMPARATIVE EFFECTIVENESS STUDY OF
SCHIZOPHRENIA TREATMENTS: ANALYSIS OF RECORD REVIEW DATA
INCORPORATING RANDOMIZATION AND PROPENSITY SCORE MATCHING
McCarrier KP1,, Durkin MB2, Dirani R2, Markowitz M2, Slabaugh SL2, Martin ML1
1Health Research Associates, Inc., Seattle, WA, USA, 2Ortho-McNeil Janssen Scientific Affairs,
LLC, Titusville, NJ, USA
OBJECTIVES: Abstraction of hospital records is currently underway at inpatient
psychiatric facilities across the United States to facilitate a large comparative ef-
fectiveness study with the following goals: 1) to observe and describe re-hospital-
ization patterns among patients with schizophrenia, and 2) to compare re-hospi-
talizaton outcomes between patients receiving paliperidone palmitate and those
receiving oral atypical antipsychotics. This abstract is intended to describe the
innovative design of this study.DESIGN/METHODS: This naturalistic record review
study incorporates several novel design elements and a unique two-phase abstrac-
tion process. In the first phase, all patients with a qualifying inpatient hospitaliza-
tion for schizophrenia are identified and basic demographic, clinical, and treat-
ment data is abstracted. From this pool of potentially-eligible patients, two groups
are identified; 1) patients discharged on paliperidone palmitate, and 2) patients
discharged on oral atypical antipsychotics. Random samples of patients are drawn
from each of these groups and designated for full data collection in phase two. In
the second review phase, these designated records are further abstracted to collect
detailed demographic variables, hospitalization and treatment history, condition
severity, comorbid conditions, and discharge characteristics. These variables are
used to model propensity scores for receipt of the target drug, and identify two
propensity-matched cohorts for the subsequent comparative effectiveness analy-
sis. Pilot testing at three hospitals has confirmed the availability of key data ele-
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ments and supports the feasibility of this approach. CONCLUSIONS: This novel
design seeks to address the bias inherent in observational research through the
imposition of randomization. By separating data collection into a preliminary
phase collecting only variables needed for treatment identification and random-
ization and a separate full review of only these randomly-selected patient records,
chart abstraction burden is minimized. Furthermore, the use of propensity score
matching to create two matched cohorts for comparison allows greater control of
potential confounding in analyses of treatment effect.
SB4
A METHODOLOGY FOR ASSESSING TREATMENT EFFECT IN THE PRESENCE OF
DISEASE SEVERITY AND COMORBIDITY IN RETROSPECTIVE OBSERVATIONAL
STUDIES
Kiri VA
PAREXEL International, Uxbridge, London, UK
OBJECTIVES: There are many examples in health outcomes research where inad-
equate control for comorbidity influence has resulted in effect estimates con-
founded by disease severity. Selection bias is a common feature of data from rou-
tine healthcare settingwhere the decision to give a particular drug to a patientwith
a given disease is generally based on patient characteristics, including disease
condition. Thus, failure to properly control for the bias could result in false associ-
ations. Propensity scores methodology is commonly used despite its limitations
because of its potential for minimising the association between exposure and con-
founding factors. We describe a methodology for assessing drug effect in longitu-
dinal data that minimises confounding by disease severity generally associated
with observational studies. METHODS: For a particular outcome of interest, we
obtain the profiles of rates ratios from two sets of matched cohorts. In set A, pa-
tients with disease X are compared with others free of X in the periods prior to and
post diagnosis of X. In set B which involves only patients with disease X, those
exposed to treatment Y are compared with those unexposed to the drug in the
periods prior to and post exposure. The two sets of profiles are then assessed using
simple regression over the respective periods. In effect, we attempt to disentangle
the disease and treatment effects. Data from the UK GPRD are used to assess
possible association between a particular outcome and treatment in COPD
RESULTS: We found evidence of association between the outcome and COPD but
none for the drug. CONCLUSIONS: The profile approach utilizes the data collected
over the disease natural history and exposure history to assess the relationships
between the outcome and both the disease and treatment. This is a key strength
often ignored when results are reported as point estimates. By design, it also mi-
nimises the effect of selection bias.
PODIUM SESSION II:
RESEARCH ON METHODS: COST-EFFECTIVENESS ANALYSIS
CE1
COST-EFFECTIVENESS SENSITIVITY ANALYSIS METHODS: A COMPARISON OF
ONE-WAY SENSITIVITY, ANALYSIS OF COVARIANCE, AND EXPECTED VALUE
OF PARTIAL PERFECT INFORMATION
Campbell J1, McQueen RB1, Libby A1, Briggs A2
1University of Colorado, Aurora, CO, USA, 2University of Glasgow, Glasgow, UK
OBJECTIVES: Advanced sensitivity methods including value of information were
developed to quantify overall decision uncertainty and to assess the cost-effective-
ness of additional research that would reduce that uncertainty. Our objective was
to compare the information gained by utilizing three alternative sensitivity meth-
ods with increasing complexity: a simple one-way sensitivity analysis; probabilis-
tic analysis of covariance (ANCOVA); and expected value of partial perfect infor-
mation (EVPPI) of input parameters. METHODS: We replicated and expanded a
published HIV/AIDS cost-effectiveness Markov model (zidovudine vs. zidovudine
plus lamivudine in the UK) using TreeAge®. Health states included three HIV/AIDS
states and death. Our outcome of interest was the incremental net monetary ben-
efit (INMB) assuming awillingness-to-pay of £20,000/QALY.We generated one-way
and probabilistic sensitivity analyses of the INMB using published input parameter
uncertainties. One-way sensitivity analysis identified the 10 most influential pa-
rameters. A total of 10,000 Monte Carlo draws were used to estimate the ANCOVA
results from the same ten parameters. EVPPI for each of the same ten parameters
was estimated specifying 1000 inner and 1000 outerMonte Carlo draws.We ranked
the parameters based on their influence on variation for each sensitivity method
and compared themusing Spearman’s rank correlation. RESULTS:Mean INMBwas
£9694 in favor of combination therapy. The two most influential inputs were the
same across all methods, contributed 78% of variation in outcome (ANCOVA), and
were the only inputs with non-zero EVPPI values. The rank order for the top ten
inputs from all methods was similar (correlation0.99 for one-way vs. ANCOVA,
0.70 for one-way vs. EVPPI and 0.70 for ANCOVA vs. EVPPI, all p-values  0.05).
CONCLUSIONS: The correlation was significant between one-way and more ad-
vanced sensitivity analyses. Although each method provides unique information,
the additional resources needed to generate advanced analyses should beweighed,
especially when the outcome decision uncertainty and therefore value of informa-
tion is low.
CE2
A NOVEL WAY OF ESTIMATING COST-EFFECTIVENESS RATIOS FROM CLINICAL
TRIALS WITH MISSING DATA: A SIMULATION STUDY
Gagnon DD1, Engelhart L2
1Thomson Reuters, Santa Barbara, CA, USA, 2DePuy, Inc., Raynham, MA, USA
OBJECTIVES: In a simulated dataset, evaluate incremental cost-effectiveness ratios
(ICERs) adjusted for covariates and missing data using three different regression
models. The regression parameter of interest is the incremental net monetary
benefit (INMB). Models are ANCOVA, mixed effects (ME), and joint mixed effects
and log time-to-dropout (joint ME), a selectionmodel.METHODS: Traditional cost-
effectiveness analysis (CEA) uses the incremental cost-effectiveness ratio (ICER), a
measurewith statistical issues and limitationswithmissing data. Regression anal-
ysis can estimate incremental net monetary benefit (INMB) and avoid these statis-
tical issues while adjusting for covariates as well as missing data. The cost-effec-
tiveness acceptability curve (CEAC) generated from a family of these regressions
can identify an ICER adjusted for the factors included in the INMB regressions (the
ICER is the point on the CEAC where the probability of being cost-effective is 50%).
Data were simulated to include missing at random (MAR) and missing not at ran-
dom (MNAR). Simulated treatment effect provided a “true” INMB for model evalu-
ations that included bias (absolute difference from “true”), precision (ratio of vari-
ances), and CEACs with willingness-to-pay () values from $0 to $100K. RESULTS:
TheANCOVA andMEmodels produced the least biased estimates. At  $50K, bias
was $1.3K, $1.4K, and 2.3K, and precision was 1.27, 0.90, and 1.24 for ME, ANCOVA,
and joint ME, respectively. The joint ME model performed best when missingness
was high. CONCLUSIONS: Once the CEACs had been generated, deriving ICERs
adjusted for covariates and missing data from those CEACs based upon INMB re-
gressions proved easy and feasible. The models used in this simulation analysis
performeddifferently under alternativemissingness conditions andwere sensitive
to nonresponsemechanisms. All estimateswere poorwhenmissingnesswas high;
suggesting prevention of missing data should be a goal of research.
CE3
COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ASSESSMENT: A
GRAPHICAL WAY TO COMBINE THE TWO FOR THE AID OF DECISION-MAKERS
Paulden M, Pham B
University of Toronto, Toronto, ON, Canada
OBJECTIVES: Cost-effectiveness analysis (CEA) has traditionally been seen as a
means of satisfying a specific and explicit social objective subject to a fixed budget
constraint. As a result, existing CEAmethods largely ignore budget impact consid-
erations in health systems where budgets are not fixed. In particular, none of the
traditional methods of presenting results (such as the cost-effectiveness plane,
ICER tables and CEAC graphs) can be used to summarize the results of a CEA and
budget impact assessment simultaneously. Our objective was to develop such a
method in a manner which is meaningful to decision makers. METHODS: We
present a novel way of combining cost-effectiveness and budget impact consider-
ations into a single graph. To do this, we disaggregate the incremental costs of the
new technology into those which fall on the health budget and displace other
technologies (resulting in forgone health) and those which lead to an expansion of
the health budget (resulting in a net budget impact). The incremental health ben-
efit of the technology and any forgone health are combined to give the net health
benefit of the technology,which is plotted against the net budget impact. RESULTS:
Our method clearly reveals the trade-off between the cost-effectiveness and
budget impact of the technology in question. This trade-off is simultaneously re-
vealed across a range of plausible values of the cost-effectiveness threshold.
CONCLUSIONS: Decision makers who are concerned with both the cost-effective-
ness and budget impact of new technologies have tended to consider each of these
separately, with the inherent trade-off between the two blurred in the process. Our
proposed method makes this trade-off explicit and does so across a range of
threshold values, enabling analysts to provide meaningful information to decision
makers while respecting decision makers’ authority in determining the appropri-
ate threshold to use.
CE4
USING DYNAMIC TRANSMISSION MODELS TO ESTIMATE THE COST
EFFECTIVENESS OF VACCINES: FOUR DIFFERENT METHODS AND THEIR
RELEVANCE FOR DECISION MAKERS
Mauskopf J1, Talbird SE1, Standaert B2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2GlaxoSmithKline Biologicals, Wavre,
Belgium
OBJECTIVES: To compare the differences in the methods used to estimate the
cost-effectiveness of vaccination programs using the clinical outcomes from dy-
namic transmission models. METHODS: A targeted electronic literature search of
title words in the PubMed databases was performed to identify studies published
since 2000 that included a description of themethods and presentation of results of
cost-effectiveness analysis of vaccination programs based on data from dynamic
transmission models for any infectious disease. Further studies were identified in
the bibliographies of the initial set of papers.RESULTS: Informationwas abstracted
from 29 papers presenting cost-effectiveness analyses of vaccination programs for
influenza, HPV, varicella virus, pertussis, meningococcal meningitis, rotavirus, H.
pylori, and hepatitis A. Both cohort and population-based estimates of cost-effec-
tiveness were presented. The population-based estimates had variable time hori-
zons from 1 year for influenza or pertussis (the steady state year) up to 100 years for
HPV, varicella, and meningococcal vaccination. All cohort analyses used a lifetime
time horizon. Four method types for the estimation and presentation of a cost-
effectiveness ratio were identified: 1) average population values (costs and bene-
fits) over a long time horizon assuming a continuing vaccination program (20 pa-
pers) 2) average population values over a long time horizon assuming a limited
duration vaccination program (1 paper) 3) population values for the steady-state
year only (1 paper) and 4) cohort values with a lifetime horizon (7 papers).
CONCLUSIONS: The variability of the estimation framework (population or cohort)
and time horizon used aswell as the variability in other input parameters observed
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